About: Clinical features and outcome of patients with acute respiratory failure revealing anti-synthetase or anti-MDA-5 dermato-pulmonary syndrome: a French multicenter retrospective study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical features and outcome of patients with acute respiratory failure revealing anti-synthetase or anti-MDA-5 dermato-pulmonary syndrome: a French multicenter retrospective study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Clinical features and outcome of patients with acute respiratory failure revealing anti-synthetase or anti-MDA-5 dermato-pulmonary syndrome: a French multicenter retrospective study
Creator	Terzi, Nicolas Voiriot, Guillaume Fartoukh, Muriel Neuville, Mathilde Quenot, Jean-Pierre Dubert, Marie Guérin, Claude Schmidt, Matthieu Guérot, Emmanuel Guitton, Christophe Schneider, Francis Maury, Eric De Prost, Nicolas Pajot, Olivier Colin, Gwenhaël Contou, Damien Coudroy, Rémi Dargent, Auguste Dumas, Guillaume Ledoux, Geoffrey Mentec, Hervé Morawiec, Elise Pineton De Chambrun, Marc Plantefève, Gaëtan Préau, Sébastien Ricome, Sylvie Zafrani, Lara Grall, Maximilien Larcher, Romaric Le Mao, Raphaël Tandjaoui-Lambiotte, Yacine Vuillard, Constance
source	PMC
abstract	BACKGROUND: Anti-synthetase (AS) and dermato-pulmonary associated with anti-MDA-5 antibodies (aMDA-5) syndromes are near one of the other autoimmune inflammatory myopathies potentially responsible for severe acute interstitial lung disease. We undertook a 13-year retrospective multicenter study in 35 French ICUs in order to describe the clinical presentation and the outcome of patients admitted to the ICU for acute respiratory failure (ARF) revealing AS or aMDA-5 syndromes. RESULTS: From 2005 to 2017, 47 patients (23 males; median age 60 [1st–3rd quartiles 52–69] years, no comorbidity 85%) were admitted to the ICU for ARF revealing AS (n = 28, 60%) or aMDA-5 (n = 19, 40%) syndromes. Muscular, articular and cutaneous manifestations occurred in 11 patients (23%), 14 (30%) and 20 (43%) patients, respectively. Seventeen of them (36%) had no extra-pulmonary manifestations. C-reactive protein was increased (139 [40–208] mg/L), whereas procalcitonine was not (0.30 [0.12–0.56] ng/mL). Proportion of patients with creatine kinase ≥ 2N was 20% (n = 9/47). Forty-two patients (89%) had ARDS, which was severe in 86%, with a rate of 17% (n = 8/47) of extra-corporeal membrane oxygenation requirement. Proportion of patients who received corticosteroids, cyclophosphamide, rituximab, intravenous immunoglobulins and plasma exchange were 100%, 72%, 15%, 21% and 17%, respectively. ICU and hospital mortality rates were 45% (n = 21/47) and 51% (n = 24/47), respectively. Patients with aMDA-5 dermato-pulmonary syndrome had a higher hospital mortality than those with AS syndrome (n = 16/19, 84% vs. n = 8/28, 29%; p = 0.001). CONCLUSIONS: Intensivists should consider inflammatory myopathies as a cause of ARF of unknown origin. Extra-pulmonary manifestations are commonly lacking. Mortality is high, especially in aMDA-5 dermato-pulmonary syndrome.
has issue date	2018-09-11(xsd:dateTime)
bibo:doi	10.1186/s13613-018-0433-3
bibo:pmid	30203297
has license	cc-by
sha1sum (hex)	8cd8139445fbf9839d4cd4c95b95b3f0d1b941d2
schema:url	https://doi.org/10.1186/s13613-018-0433-3
resource representing a document's title	Clinical features and outcome of patients with acute respiratory failure revealing anti-synthetase or anti-MDA-5 dermato-pulmonary syndrome: a French multicenter retrospective study
has PubMed Central identifier	PMC6131681
has PubMed identifier	30203297
schema:publication	Ann Intensive Care
resource representing a document's body	covid:8cd8139445fbf9839d4cd4c95b95b3f0d1b941d2#body_text
is schema:about of	named entity 'patients' named entity 'responsible' named entity 'ARF' named entity 'DERMATO' named entity 'INFLAMMATORY MYOPATHIES' named entity 'severe' named entity 'retrospective study' named entity 'Clinical' named entity 'autoimmune' named entity 'ICUs' named entity 'ICU' named entity 'inflammatory myopathies' named entity 'antibodies' named entity 'retrospective study' named entity 'case series' named entity 'rheumatologists' named entity 'ARF' named entity 'ARDS' named entity 'etiology' named entity 'heterogeneity' named entity 'lung' named entity 'intensive care unit' named entity 'ARDS' named entity 'microbiological' named entity 'lung' named entity 'MDA-5' named entity 'autoantibody' named entity 'periungual' named entity 'ARF' named entity 'infection' named entity 'risk factor' named entity 'myositis' named entity 'myositis' named entity 'pneumonia' named entity 'ECMO' named entity 'lung' named entity 'Cytological' named entity 'ICU' named entity 'ICU' named entity 'ECMO' named entity 'lung infection' named entity 'mortality rates' named entity 'lung' named entity 'autoimmune' named entity 'Jo-1' named entity '0.21' named entity 'organizing pneumonia' named entity 'MDA-5' named entity 'extra-corporeal membrane oxygenation' named entity 'ICU'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software